Raisanberine protected pulmonary arterial rings and cardiac myocytes of rats against hypoxia injury by suppressing NADPH oxidase and calcium influx

Acta Pharmacologica Sinica

Volumn 33, Issue 5, 2012, Pages 625-634

  Gao, Jie ^a   Tang, Yi Qun ^a   Dai, De Zai ^a   Cheng, Yu Si ^a   Zhang, Guo Lin ^a   Zhang, Can ^a   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Apocynin; Calcium influx; Cardiac myocytes; Hypoxia; NADPH oxidase; Nifedipine; Pulmonary artery; Raisanberin

Indexed keywords

ACETYLCHOLINE; APOCYNIN; BERBERINE DERIVATIVE; CALCIUM; HYDROGEN PEROXIDE; N(G) NITROARGININE; NIFEDIPINE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; RAISANBERINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; COMPUTER SYSTEM; CONTROLLED STUDY; DRUG MEGADOSE; FLUORESCENCE ANALYSIS; HEART MUSCLE CELL; HYPOXIA; INJURY; INTERMITTENT HYPOXIA; MALE; NONHUMAN; PULMONARY ARTERY; RAT; VASOCONSTRICTION;

ADMINISTRATION, ORAL; ANIMALS; ANOXIA; ANTIOXIDANTS; ARTERIOLES; BERBERINE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CALCIUM SIGNALING; CELLS, CULTURED; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME INHIBITORS; MALE; MYOCYTES, CARDIAC; NADPH OXIDASE; NITRIC OXIDE; OXIDATIVE STRESS; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; TIME FACTORS; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 84860761952     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.7     Document Type: Article

References (31)

1. Hernandez-Rivera H, Martinez-Gonzalez H, Casal J, Rodriguez-Ospina L. Pulmonary arterial hypertension: from pathophysiology to management. Bol Asoc Med P R 2011; 103: 34-40.
2. Yuan SH, Dai DZ, Guan L, Dai Y, Ji M. CPU0507, an endothelin receptor antagonist, improves rat hypoxic pulmonary artery hypertension and constriction in vivo and in vitro. Clin Exp Pharmacol Physiol 2006; 33: 1066-72. (Pubitemid 44581569)
3. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008; 31: 407-15.
4. Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA, et al. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010; 468: 1115-8.
5. Peng HJ, Dai DZ, Ji H, Dai Y. The separate roles of endothelin receptors participate in remodeling of matrix metalloproteinase and connexin 43 of cardiac fibroblasts in maladaptive response to isoproterenol. Eur J Pharmacol 2010; 634: 101-6.
6. Dai DZ, Dai Y. Role of endothelin receptor A and NADPH oxidase in vascular abnormalities. Vasc Health Risk Manag 2010; 6: 787-94.
7. Cui B, Yu F, Dai DZ, Zhang TT, Tang XY, Dai Y. CPU0213, a novel endothelin receptor antagonist, relieves hypoxic pulmonary hypertension in rats by suppressing excessive ET-ROS pathway. Drug Dev Res 2007; 68: 42-52.
8. Zhang TT, Cui B, Dai DZ, Tang XY. Pharmacological efficacy of CPU 86017 on hypoxic pulmonary hypertension in rats: mediated by direct inhibition of calcium channels and antioxidant action, but indirect effects on the ET-1 pathway. J Cardiovasc Pharmacol 2005; 46: 727-34. (Pubitemid 44378242)
9. Li N, Dai D, Dai Y. CPU86017 and its isomers improve hypoxic pulmonary hypertension by attenuating increased ETA receptor expression and extracellular matrix accumulation. Naunyn-Schmiedeberg's Arch Pharmacol 2008; 378: 541-52.
10. Nisbet RE, Graves AS, Kleinhenz DJ, Rupnow HL, Reed AL, Fan TH, et al. The role of NADPH oxidase in chronic intermittent hypoxia-induced pulmonary hypertension in mice. Am J Respir Cell Mol Biol 2009; 40: 601-9.
11. Selemidis S, Sobey CG, Wingler K, Schmidt HH, Drummond GR. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 2008; 120: 254-91.
12. Report. UAD, (Ed.) URDS. Research from the national institutes of Health, national Institute of diabetes and digestive kidney disease, and Charles R. Drew University of Medicine and Science High School Student Research Program-Summer 2005. Ethn Dis 2006; 16: 1-39.
13. Su W, Dai DZ, Liu HR, Na T, Dai Y. Upregulated endothelin system in diabetic vascular dysfunction and early retinopathy is reversed by CPU0213 and total triterpene acids from fructus corni. Clin Exp Pharmacol Physiol 2007; 34: 1228-33. (Pubitemid 350013233)
14. Li N, Jia N, Dai DZ, Dai Y. Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: a role of hyperphosphorylation of PKCepsilon. Eur J Pharmacol 2008; 591: 211-8.
15. Qi MY, Feng Y, Dai DZ, Li N, Cheng YS, Dai Y. CPU86017, a berberine derivative, attenuates cardiac failure through normalizing calcium leakage and downregulated phospholamban and exerting antioxidant activity. Acta Pharmacol Sin 2010; 31: 165-74.
16. Zhang TT, Cui B, Dai DZ, Su W. CPU 86017, p-chlorobenzyltetrahyd roberberine chloride, attenuates monocrotaline-induced pulmonary hypertension by suppressing endothelin pathway. Acta Pharmacol Sin 2005; 26: 1309-16. (Pubitemid 41607002)
17. Li N, Yang L, Dai DZ, Wang QJ, Dai Y. Chiral separation of racemate CPU86017, an anti-arrhythmic agent, produces stereoisomers possessing favourable ion channel blockade and less alpha-adrenoceptor antagonism. Clin Exp Pharmacol Physiol 2008; 35: 643-50. (Pubitemid 351490098)
18. Luo L, Dai D, Cheng Y, Zhang Q, Yuan W, Dai Y. Sildenafil improves diabetic vascular activity through suppressing endothelin receptor A, iNOS and NADPH oxidase which is comparable with the endothelin receptor antagonist CPU0213 in STZ-injected rats. J Pharm Pharmacol 2011; 63: 943-51.
19. Hu C, Yu F, Dai DZ, Dai Y. Stress-up-regulated myocardial endothelin receptors are suppressed by chlorobenzyltetrahydroberberine CPU86017 and its RS chiral isomer. J China Pharm Univ 2009; 40: 374-9.
20. Huang ZJ, Dai DZ, Li N, Na T, Ji M, Dai Y. Calcium antagonist property of CPU228, a dofetilide derivative, contributes to its low incidence of torsades de pointes in rabbits. Clin Exp Pharmacol Physiol 2007; 34: 310-7.
21. Mirza MA, Zhang XQ, Ahlers BA, Qureshi A, Carl LL, Song J, et al. Effects of phospholemman downregulation on contractility and [Ca2+] i transients in adult rat cardiac myocytes. Am J Physiol Heart Circ Physiol 2004; 286: H1322-30. (Pubitemid 38381139)
22. Yuan SH, Li N, Dai DZ. The different vasomotor of pulmonary and tail arteries from two pulmonary hypertension rat models and in vitro drug intervention. Prog Pharm Sci 2006; 30: 314-21.
23. Cui B, Cheng YS, Dai DZ, Li N, Zhang TT, Dai Y. CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats. Clin Exp Pharmacol Physiol 2009; 36: 169-75.
24. Galiè N, Negro L, Simonneau G. The use of combination therapy in pulmonary arterial hypertension: new developments. Eur Respir Rev 2009; 18: 148-53.
25. De Giusti VC, Correa MV, Villa-Abrille MC, Beltrano C, Yeves AM, de Cingolani GE, et al. The positive inotropic effect of endothelin-1 is mediated by mitochondrial reactive oxygen species. Life Sci 2008; 83: 264-71.
26. Zeng Q, Zhou Q, Yao F, O'Rourke ST, Sun C. Endothelin-1 regulates cardiac L-type calcium channels via NAD(P)H oxidase-derived superoxide. J Pharmacol Exp Ther 2008; 326: 732-8.
27. Xu J, Yu F, Dai DZ, Dai Y. High glucose-induced vascular dysfunction and expression of vascular ET-AR and OB-Rb: intervention effects of ETR antagonist CPU0213. Prog Pharm Sci 2009; 3: 125-31.
28. Dennis KE, Aschner JL, Milatovic D, Schmidt JW, Aschner M, Kaplowitz MR, et al. NADPH oxidases and reactive oxygen species at different stages of chronic hypoxia-induced pulmonary hypertension in newborn piglets. Am J Physiol Lung Cell Mol Physiol 2009; 297: L596-607.
29. Sedeek M, Callera G, Montezano A, Gutsol A, Heitz F, Szyndralewiez C, et al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol 2010; 299: F1348-58.
30. Wang YX, Zheng YM. ROS-dependent signaling mechanisms for hypoxic Ca2+ responses in pulmonary artery myocytes. Antioxid Redox Signal 2010; 12: 611-23.
31. Amberg GC, Earley S, Glapa SA. Local regulation of arterial L-type calcium channels by reactive oxygen species. Circ Res 2010; 107: 1002-10.